PharmGen Science, Inc. (KRX:004720)

PharmGen Science Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	117.75	2,791	6,089	70,060	32,466	9,222
Depreciation & Amortization	4,628	4,636	4,247	3,371	3,142	2,963
Loss (Gain) From Sale of Assets	16.83	16.83	-46.35	-1.94	11.49	29.13
Asset Writedown & Restructuring Costs	-	-	228.3	133.08	799.9	53.75
Loss (Gain) From Sale of Investments	3,061	3,061	-51.6	-9.77	-1.11	1,085
Loss (Gain) on Equity Investments	7,355	4,916	2,539	-87,213	-46,633	-14,508
Stock-Based Compensation	-	-	-	-	4,359	1,671
Provision & Write-off of Bad Debts	96.01	195.85	-125.07	-289.72	5.11	1,243
Other Operating Activities	-279.54	950.05	-907.05	25,467	9,532	5,866
Change in Accounts Receivable	-3,374	-3,878	-7,454	-7,901	1,433	-3,480
Change in Inventory	-12,266	-11,132	186.91	-5,675	1,195	-2,639
Change in Accounts Payable	48.91	1,753	-70.57	433.75	24.39	398.27
Change in Other Net Operating Assets	-691.33	-925.88	804.17	340.48	1,450	771.63
Operating Cash Flow	-1,287	2,384	5,439	-1,286	7,784	2,676
Operating Cash Flow Growth	-	-56.16%	-	-	190.93%	6.03%

Investing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Capital Expenditures	-652.9	-918.7	-2,266	-9,922	-30,750	-4,339
Sale of Property, Plant & Equipment	28.28	28.28	80	190.25	46.58	5.3
Sale (Purchase) of Intangibles	-1,803	-1,865	-985.79	-2,034	-3,260	-582.75
Investment in Securities	1,500	1,500	6,490	-3,498	1,501	-550
Other Investing Activities	368.19	365.88	-58.67	-20.38	2,077	-2,254
Investing Cash Flow	-559.59	-889.45	3,260	-15,284	-30,385	-7,721

Financing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Short-Term Debt Issued	-	-	-	389.68	1,169	-
Long-Term Debt Issued	-	-	11,200	33,300	49,779	20,500
Total Debt Issued	-	-	11,200	33,690	50,948	20,500
Short-Term Debt Repaid	-	-	-	-2,338	-	-
Long-Term Debt Repaid	-	-751.26	-2,633	-30,880	-20,428	-983.48
Total Debt Repaid	-20,754	-751.26	-2,633	-33,218	-20,428	-983.48
Net Debt Issued (Repaid)	-20,754	-751.26	8,567	471.8	30,521	19,517
Other Financing Activities	268.65	267.31	284.59	1,797	-180.05	51.18
Financing Cash Flow	-20,486	-483.95	8,852	2,269	30,340	19,568

Net Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Miscellaneous Cash Flow Adjustments	-0	-0	0	-	-	0
Net Cash Flow	-22,332	1,011	17,551	-14,302	7,739	14,523

Free Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Free Cash Flow	-1,940	1,466	3,173	-11,208	-22,966	-1,664
Free Cash Flow Growth	-	-53.81%	-	-	-	-
Free Cash Flow Margin	-1.13%	0.86%	1.90%	-7.43%	-20.90%	-1.72%
Free Cash Flow Per Share	-91.07	67.29	152.58	-519.12	-1234.84	-110.74
Levered Free Cash Flow	-10,260	-7,432	-6,644	-8,116	-23,020	-6,110
Unlevered Free Cash Flow	-7,662	-4,834	-3,979	-5,922	-21,944	-5,929

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash Interest Paid	1,537	1,544	2,112	1,718	1,112	297.81
Cash Income Tax Paid	764.89	131.67	2,124	52.99	866.9	209.36
Change in Working Capital	-16,282	-14,183	-6,534	-12,802	4,102	-4,950

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error